CLINICAL STUDIES

EFPEGLENATIDE

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk

Study Phase:

Phase 3

Criteria:

  • Male or Female 18 years or older
  • Type 2 Diabetes Mellitus (T2DM)
  • HbA1C ≥ 7.0%.
  • History of Cardiovascular Event
Register